HA
AVIR icon

HHLR Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

HHLR Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-125,000
Closed -$5.22M – 94
2020
Q4 		$5.22M Buy
+125,000
New +$4.03M 0.04% 84

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

HHLR Advisors's AVIR Position: Q1 2021 in Review

HHLR Advisors sold out of Atea Pharmaceuticals (AVIR) in Q1 2021, closing a stake of 125,000 shares — an estimated $5.22M sold.

HHLR Advisors first reported a position in AVIR in Q4 2020 and held it in 1 quarter. The position peaked at $5.22M in Q4 2020. 81 funds tracked by Wall St. Rank hold AVIR as of Q1 2021.

  • HHLR Advisors reported no remaining Atea Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • HHLR Advisors sold 125,000 Atea Pharmaceuticals shares in Q1 2021, an estimated $5.22M.
  • HHLR Advisors first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • HHLR Advisors's Atea Pharmaceuticals position peaked at $5.22M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2021.

Based on HHLR Advisors's 13F filing for Q1 2021, filed 17 May 2021.